Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 3Completed 3Withdrawn 2Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Pain, Postoperative 1Pain 1Breast Neoplasms 1Brain Neoplasms 1Bites and Stings 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Lidocaine × Clear all
NCT02121951 2018-04-10

QLB

National Cancer Institute, Egypt

Phase 4 Withdrawn

Bites and Stings, Neoplasms

NCT00321347 2012-06-22

Intravenous (IV) Lidocaine for Opioid-refractory Pain

San Diego Hospice & Palliative Care

Phase 2 Withdrawn

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡